Navigation Links
Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development
Date:3/11/2008

STRASBOURG, France, March 11 /PRNewswire-FirstCall/ -- Transgene (Euronext Paris: FR0005175080) announces today its achievements in operations, financial performance for 2007 and outlook for 2008.

"2007 was a breakthrough year for Transgene, marked by two major accomplishments: the signing of a partnership agreement with Roche in the domain of therapeutic vaccines for the treatment of diseases caused by the HPV virus, and the successful completion of a EUR100.1m capital increase on European markets," declared Philippe Archinard, Managing Director of Transgene.

Key financial highlights include:

- Total revenues for the year were EUR28million compared to EUR5.5m in 2006.

- Transgene closed the year with a net loss of EUR5.5m compared to a net loss of EUR22m a year earlier.

- Basic loss per ordinary share was EUR0.28 versus EUR1.41 in 2006.

- Research and development expenditures were EUR28.8m compared to EUR24.2m in 2006.

- In 2007, net cash expenditure, excluding capital increase, was EUR5.5m compared to EUR20.7m in 2006.

- At the end of 2007, the company held cash and cash equivalents of EUR111.3m, which should enable it to finance some four years of operating costs.

Major Accomplishments of 2007:

Partnership Roche /Transgene: announced in April 2007, an exclusive world wide license agreement aimed at the development, registration and commercialisation of Transgene's therapeutic vaccines developed to fight diseases caused by the Human Papilloma Virus. Transgene received an upfront payment and a regulatory milestone of EUR23m in June 2007 and may receive further payments of up to EUR195m covering clinical development milestones and commercial milestones based on future sales of HPV products, stemming from Transgene's research. Under the terms of the agreement, Transgene is also entitled to receive progressive, double digit royalties on all future sales.

Strengthening of the Equity Bas
'/>"/>

SOURCE Transgene S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
2. Transgene: Cash Position of EUR 119 Million as of September 30, 2007
3. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
4. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
5. Medline and 3M Agree to Strategic Partnership in Electrosurgery
6. Partnership With SearchMedica.com to Enhance Web Searches on ModernMedicine.com
7. B-Line Medical and Immersion Medical Announce Partnership
8. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
9. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
10. ExonHit and bioMerieux Amend Their Strategic Partnership
11. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015  InCarda Therapeutics, Inc. (InCarda), a ... commercialization of therapies for acute cardiovascular conditions via ... a Series A financing. In this financing, InCarda ... an additional $1.5 million. The lead investor in ... a consortium of physicians and other health care ...
(Date:4/28/2015)... ARBOR, Mich. , April 28, 2015 ... Therapy today shows that the Paradigm Cancer Diagnostic ... across a number of key clinical variables, including turnaround ... The purpose of the analysis was to interrogate and ... cancer patients compared with each other.  ...
(Date:4/28/2015)... Maryland (PRWEB) April 28, 2015 ... Warehouse that bring it to the web and ... features and user friendly reporting metrics increase data ... reports for convenient recall and access “on-the-go” makes ... was built using client feedback to assist in ...
(Date:4/28/2015)... 28, 2015 Reproductive endocrinologist Dr. Kaylen ... 7 couples battling infertility in this country, testified on behalf ... as the first state in the nation to consider creating ... to couples who desire to receive them. , Infertility affects ... that infertility is one of the few medical diseases that ...
Breaking Biology Technology:InCarda Therapeutics Completes Over $5 Million Private Financing 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3
... Inc. announced today that it has initiated patient enrollment ... lead product candidate TG-C.  TG-C involves human allogeneic chondrocytes ... regeneration of cartilage in patients suffering from severe osteoarthritis ... placebo-controlled Phase II study will evaluate the safety and ...
... animals grew far more complex than their single-celled ancestors. ... finds that complex organisms, including humans, have accumulated structural ... from microbe to man. The study, published in ... errors into proteins, rather than traditional natural selection, may ...
... 2011 Cellectis bioresearch, a subsidiary of Cellectis ... Wako Pure Chemical Industries as its distributor in ... products and services, including the recently launched TALEN(1) ... distributor of research products in Japan. ...
Cached Biology Technology:TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee 2Errors in protein structure sparked evolution of biological complexity 2Errors in protein structure sparked evolution of biological complexity 3Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan 2
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... 14, 2012) A research team has identified epigenetic ... gene expression, within reprogrammed skin cells. These signatures can ... skin cells or induced pluripotent stem cells (iPSCs), cells ... the expression of the protein is controlled brings us ...
... GABLES, FL (March 14, 2012)--Convincing speeches are central to campaigning ... select our leaders? A newly-published paper in Proceedings of ... and women vote for male and female candidates with lower-pitched ... to be perceived as more competent, stronger, and more trustworthy. ...
... to testicular cells than titanium dioxide nanoparticles, according to ... Health. However, the use of both types may affect ... Commonly used Nanotechnology is increasingly ... potential risks of using engineered nanoparticles need to be ...
Cached Biology News:Epigenetic signatures direct the repair potential of reprogrammed cells 2Are silver nanoparticles harmful? 2
... α-Secretase Activity Kit ADAM17 Activity ... 96 Tests. PROTECT FROM LIGHT. AVOID ... is a specific and sensitive assay designed ... lysates and biological samples and for screening ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
... EnzChek Pyrophosphate Detection Kit,provides a fast, ... the inorganic pyrophosphate (PPi ) produced,by ... as DNA and,RNA polymerizations, cyclic AMP ... the enzymatic activation of fatty acids ...
... (TdT) is an intracellular marker normally present ... minor subpopulation of bone marrow prelymphocytes. Elevated ... of TdT cells are found to be ... Presence of TdT thus provides a useful ...
Biology Products: